These are top 10 stocks traded on the Robinhood UK platform in July
On Friday, Goldman Sachs revised its stance on ICON plc (NASDAQ:ICLR), downgrading the stock from Buy to Neutral and reducing the price target from $250.00 to $200.00. The shift in rating comes as the firm adjusts its perspective on the near-term outlook for the company, a prominent player in the Clinical Research Organization (CRO) industry. With a market capitalization of $14.86 billion and trading near its 52-week low, InvestingPro analysis suggests the stock is currently undervalued, despite 12 analysts recently revising their earnings expectations downward.
Matthew Sykes of Goldman Sachs initially supported ICON due to its clear growth narrative, consistent performance, and potential for sustained growth and margin expansion, which justified its higher valuation compared to peers. However, the company’s recent performance has not been as consistent as expected, and a weaker demand environment has led to a revised view. The company maintains a strong gross profit margin of 29.5% and an impressive Piotroski Score of 8, indicating solid financial health.
Despite the downgrade, Goldman Sachs acknowledges ICON’s leadership in the clinical CRO space and anticipates it will benefit from vendor consolidation over time. The firm also expresses confidence in ICON’s execution capabilities once the broader demand environment improves. This improvement, however, is now forecasted to occur later than previously expected, with a new timeline extending into late 2025 and 2026, rather than the second half of 2024.
The current valuation of ICON at approximately 11 times EBITDA, down from around 15.5 times at the initiation, is seen as attractive relative to the company’s historical valuation. Nevertheless, Goldman Sachs cautions that valuation should not be regarded as a dependable near-term support level due to the current uncertain demand trends.
In other recent news, ICON plc reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with earnings per share (EPS) of $3.43 and revenue of $2.04 billion, slightly above forecasts. Despite the positive earnings report, ICON is experiencing a delay in a significant next-generation COVID vaccine study, which is expected to resume in the second quarter of 2025. This delay is anticipated to impact the company’s revenue for the first half of 2025 by approximately $40-80 million, though ICON has maintained its full-year 2025 guidance.
Truist Securities has maintained a Buy rating on ICON, with a price target of $262, expressing confidence in the company’s long-term prospects despite the temporary setback. Similarly, Evercore ISI has reiterated its Outperform rating with a price target of $225, acknowledging the delay but maintaining a positive outlook for ICON. Meanwhile, Leerink Partners has adjusted its price target for ICON to $235 from $243, while maintaining an Outperform rating, citing additional market-driven challenges due to the trial delay.
ICON’s management has stated that the postponement will affect 1-2% of the company’s revenue for the first half of 2025 but expects no change to its full-year guidance. The company plans to focus on digital innovation and automation to enhance trial completion rates and cost savings. As analysts and investors continue to monitor ICON’s performance, the company remains committed to navigating the challenges posed by the study’s delay and maintaining its strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.